125 related articles for article (PubMed ID: 20414022)
1. [Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
Kurihara T; Kobayashi M; Kogo M; Yoneyama K; Ito N; Sunaga T; Konishi K; Imawari M; Tobe T; Kiuchi Y
Gan To Kagaku Ryoho; 2010 Apr; 37(4):659-64. PubMed ID: 20414022
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Zhou J; Zhao R; Wen F; Zhang P; Tang R; Du Z; He X; Zhang J; Li Q
Med Oncol; 2015 Apr; 32(4):121. PubMed ID: 25788034
[TBL] [Abstract][Full Text] [Related]
3. [Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Sasajima J; Tanno S; Koizumi K; Nakano Y; Habiro A; Chiba A; Fujii T; Sugiyama Y; Nakamura K; Nishikawa T; Mizukami Y; Okumura T; Kohgo Y
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1657-61. PubMed ID: 19838023
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Zhou J; Zhao R; Wen F; Zhang P; Wu Y; Tang R; Chen H; Zhang J; Li Q
Tumori; 2016 Jun; 2016(3):294-300. PubMed ID: 27056335
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
6. S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Liao W; Huang J; Zhu G; Zhou J; Wen F; Zhang P; Zhou K; Wu Q; Wang X; Gou H; Li Q
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):133-138. PubMed ID: 31597496
[No Abstract] [Full Text] [Related]
7. Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stainthorpe A; Greenhalgh J; Bagust A; Richardson M; Boland A; Beale S; Duarte R; Kotas E; Banks L; Palmer D
Pharmacoeconomics; 2018 Oct; 36(10):1153-1163. PubMed ID: 29600384
[TBL] [Abstract][Full Text] [Related]
8. Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Gharaibeh M; McBride A; Bootman JL; Patel H; Abraham I
J Med Econ; 2017 Apr; 20(4):345-352. PubMed ID: 27919186
[TBL] [Abstract][Full Text] [Related]
9. [A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Hatata T; Takaya S; Taniguchi K; Naka T; Kondo A; Ikeguchi M
Gan To Kagaku Ryoho; 2011 Jan; 38(1):109-12. PubMed ID: 21368469
[TBL] [Abstract][Full Text] [Related]
10. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M
JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Slack M; Erstad B; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Oct; 36(10):1273-1284. PubMed ID: 29948964
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy.
Wu B; Li T; Cai J; Xu Y; Zhao G
BMC Cancer; 2014 Dec; 14():984. PubMed ID: 25526802
[TBL] [Abstract][Full Text] [Related]
13. [A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Kuji M; Yamamoto Y; Tani C; Kenno S; Kobayashi T
Gan To Kagaku Ryoho; 2011 May; 38(5):853-5. PubMed ID: 21566453
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
Shin S; Park CM; Kwon H; Lee KH
BMC Cancer; 2016 Jul; 16():443. PubMed ID: 27400734
[TBL] [Abstract][Full Text] [Related]
15. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
Jpn J Clin Oncol; 2021 Apr; 51(4):604-611. PubMed ID: 33479765
[TBL] [Abstract][Full Text] [Related]
16. [A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
Kawasaki H; Kukita K; Mizushima Y; Hirata K
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1239-42. PubMed ID: 18633272
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
Hara T; Nagata M; Yamashita Y; Fujimoto K; Muraki Y; Yasuda Y; Kurahashi T
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1233-7. PubMed ID: 18633271
[TBL] [Abstract][Full Text] [Related]
18. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Gharaibeh M; McBride A; Alberts DS; Erstad B; Slack M; Alsaid N; Bootman JL; Abraham I
Pharmacoeconomics; 2018 Nov; 36(11):1333-1343. PubMed ID: 29981004
[TBL] [Abstract][Full Text] [Related]
19. [A case of recurrent pancreatic cancer with lung metastasis responding to S-1 combined gemcitabine chemotherapy].
Fukada I; Ikeda H; Yamaguchi K; Okabe M; Tsuruta A; Morimoto Y; Kawamoto K; Sano K; Paku T; Imai S; Yoshida Y; Ito T; Ogasahara K
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1733-6. PubMed ID: 19838037
[TBL] [Abstract][Full Text] [Related]
20. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
Miyagawa K; Yata Y; Yamaoka N; Sagara Y
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
